FDPS抗体;FDPS Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P10149(FDPS Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P10149(FDPS Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

**Background of FDPS Antibody**

Farnesyl Diphosphate Synthase (FDPS) is a key enzyme in the mevalonate pathway, catalyzing the synthesis of farnesyl diphosphate (FPP), a precursor for cholesterol, steroid hormones, and lipid-modified proteins. FDPS plays a critical role in cellular processes, including membrane integrity, protein prenylation, and signaling pathways. Dysregulation of FDPS is linked to diseases such as cancer, osteoporosis, and metabolic disorders, making it a therapeutic target. For instance, nitrogen-containing bisphosphonates (N-BPs), drugs used to treat bone resorption in osteoporosis and metastatic bone disease, inhibit FDPS to disrupt osteoclast function.

FDPS antibodies are essential tools for studying the enzyme's expression, localization, and function in various tissues and disease models. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to quantify FDPS levels in cancer cells, bone tissue, or metabolic studies. Researchers also employ these antibodies to explore FDPS's role in drug resistance mechanisms, particularly in cancers treated with bisphosphonates or statins. Additionally, FDPS antibodies aid in validating the efficacy of emerging therapies targeting the mevalonate pathway. Their specificity and reliability are crucial for understanding FDPS-related disease mechanisms and advancing translational research.